In a report released today, Raju Prasad from William Blair maintained a Buy rating on Rocket Pharmaceuticals Inc (RCKT). The company’s shares closed yesterday at $16.16.
According to TipRanks.com, Prasad is a 1-star analyst with an average return of -4.5% and a 25.5% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Logicbio Therapeutics Inc, and Audentes Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Rocket Pharmaceuticals Inc.
See today’s analyst top recommended stocks >>
Based on Rocket Pharmaceuticals Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $16.09 million. In comparison, last year the company had a GAAP net loss of $7.4 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, devastating diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms.
